This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TROV Cardiff Oncology (TROV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:TROV) Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$1.54▼$1.6250-Day Range$1.19▼$24.7152-Week Range$0.70▼$3.46Volume885,068 shsAverage Volume648,892 shsMarket Capitalization$17.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. Read More Receive TROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TROV Stock News HeadlinesCardiff Oncology Shareholders Approve Directors and Equity PlanJune 11, 2026 | tipranks.comCardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational StudyJune 2, 2026 | quiverquant.comQNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.' He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year. | Brownstone Research (Ad)Cardiff Oncology Faces License Termination Dispute Over OnvansertibMay 29, 2026 | tipranks.comCardiff Oncology to Host Investor Webcast on June 3 for CRDF-004 Data Update in RAS-Mutated Metastatic Colorectal Cancer TrialMay 21, 2026 | quiverquant.comQCardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026April 21, 2026 | quiverquant.comQCardiff Oncology Names Interim CEO to Role on Permanent Basis; Appoints CFOApril 9, 2026 | marketwatch.comCardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 19, 2026 | markets.businessinsider.comSee More Headlines TROV Stock Analysis - Frequently Asked Questions How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:TROV) issued its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%. When did Cardiff Oncology's stock split? Shares of Cardiff Oncology reverse split on the morning of Wednesday, February 20th 2019.The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA Royalty (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV). Company Calendar Last Earnings2/27/2020Today6/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TROV CIK1213037 Webwww.trovagene.com Phone(858) 952-7570FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.41 million Net Margins-3,688.31% Pretax MarginN/A Return on Equity-202.00% Return on Assets-122.92% Debt Debt-to-Equity Ratio0.12 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$250 thousand Price / Sales68.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book1.66Miscellaneous Outstanding Shares11,011,000Free FloatN/AMarket Cap$17.18 million OptionableNot Optionable Beta1.04 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:TROV) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
